COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System

Hilal Abboud¹, Fatima Zahra Abboud⁴, Hanane Kharbouch², Yasser Arkha¹, Najia El Abbadi³, Abdessamad El Ouahabi¹

Key words
- COVID-19
- Long-term consequence
- Nervous system
- Pathophysiology
- SARS-Cov-2

Abbreviations and Acronyms
ACE: Angiotensin-converting enzyme
ANE: Acute necrotizing encephalopathy
CNS: Central nervous system
COVID-19: Coronavirus disease 2019
CSF: Cerebrospinal fluid
CT: Computed tomography scan
GBS: Guillain-Barre syndrome
MERS-CoV: Middle East Respiratory Syndrome Coronavirus
SARS: Severe acute respiratory syndrome
SARS-CoV: Severe acute respiratory syndrome coronavirus
SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2
T cells: Thymus cells

INTRODUCTION
The clinical course of COVID-19 ranges from asymptomatic infection to severe acute respiratory distress with multiorgan involvement and death. The disease can cause extrapulmonary complications such as neurologic disorders, which are increasingly reported in the literature. Understanding the nervous system involvement pathways and neurologic manifestations can be useful in improving assessment and management of SARS-CoV-2 patients. Indeed, these disorders may interfere with the prognosis or require treatment modification.

SARS-CoV-2 AND THE NERVOUS SYSTEM: A WELL-ESTABLISHED LINK
Although pneumonia is the most frequent manifestation of COVID-19, many other extrapulmonary involvements including nervous system have been reported. Given high rates of COVID-19 infection in the general population, coincidental occurrence of neurologic events is likely. However, currently there is convincing evidence that SARS-CoV-2 can involve the nervous system, and its neurotropic potential is increasingly well established.

SARS-CoV-2 and SARS-CoV: High Similarities
Genomic analysis shows that SARS-CoV-2 is in the same beta-coronavirus clade as MERS-CoV and SARS-CoV and shares a highly homologic sequence with SARS-CoV. In addition, the entry of SARS-CoV-2 into human host cells has been identified to use the same receptor as SARS-CoV.
structure and infection pathway, and therefore the infection mechanisms and neurotropism previously found for other coronavirus may also be applicable for SARS-CoV-2.

SARS-CoV and SARS-CoV-2: A Documented Neuroinvasion

Previous autopsy studies identified SARS-CoV in brain tissue from both patients with significant central nervous system symptoms and experimental animals. Recently, a Japanese team reported a young patient with convulsions and unconsciousness; he was diagnosed with aseptic encephalitis with SARS-CoV-2 ribonucleic acid in cerebrospinal fluid (CSF). SARS-CoV-2 has also been identified in the CSF of a 56-year-old male who developed COVID-19 in China; this case remains unpublished in peer-reviewed literature but has been cited by other papers. Note that viral particles were also identified in brain tissue from postmortem examination of a SARS-CoV-2–infected patient.

Neurologic Complications Related to Coronavirus

Published case series of other corona respiratory viruses like MERS-CoV and SARS-CoV in prior years have listed many neurologic complications including intracranial hemorrhage, ischemic stroke, polyneuropathy, encephalitis, and Guillain-Barre syndrome.

MECHANISMS OF NEUROINVASION AND REPERCUSSIONS ON THE NERVOUS SYSTEM

Direct Brain Invasion

Direct Involvement. Dissemination across the cribriform plate of the ethmoid bone during the infection can lead to cerebral invasion; this was reported in SARS-CoV (Figure 1).

Neuronal Pathway. Altered sense of smell and/or taste in uncomplicated early-stage COVID-19 patients is suggestive of a movement of the virus to the brain via the olfactory bulb, which enables the virus to reach and affect the brain.

Blood Circulation Pathway and ACE2 Receptor. SARS-CoV-2 has been shown to use the ACE2 receptor for cell entry. This receptor has also been detected over glial cells and neurones, which make it a potential target for COVID-19. Moreover, SARS-CoV-2 spike protein could interact with ACE2 expressed in the capillary endothelium; the virus may also damage the blood-brain barrier and enter...
the CNS by attacking the vascular system.\textsuperscript{7,10}

**Indirect Effects on the Central Nervous System**

**Hypoxia.** When a virus replicates and proliferates in pneumocytes, it causes diffuse alveolar and interstitial inflammatory exudate, as well as the formation of membranes in the most severe forms. This, in turn, leads to alveolar gas exchange disorders causing hypoxia in the CNS, increasing the anaerobic metabolism in brain cells, inducing cellular and interstitial edema, obstructing cerebral flow blood, as well as ischemia and vasodilation in the cerebral circulation.\textsuperscript{5-9}

**ACE\textsubscript{2}, Hypertension, and Coagulopathy.** SARS-Cov-2 binds to ACE\textsubscript{2} with a high affinity compared with SARS-CoV.\textsuperscript{20} ACE\textsubscript{2} is known to be a cardiocerebral vascular protection factor, playing a major role in regulating blood pressure and antiatherosclerosis mechanisms. Binding to ACE\textsubscript{2}, the previously mentioned viruses may cause abnormally elevated blood pressure and increase the risk of cerebral hemorrhage and ischemic stroke.

In addition, patients with COVID-19 often suffer from coagulopathy and prolonged prothrombin time,\textsuperscript{11,12} both of which are also contributing factors to secondary cerebral hemorrhage.

**Immune-Mediated neurologic Injury.** The immune response can also play a role. Some patients with COVID-19 have died from hyperinflammatory syndrome (cytokine storm) and multiorgan failure.\textsuperscript{23} Coronavirus have the ability to infect macrophages and glial cells. Experimental models have shown that glial cells are capable of secreting proinflammatory factors, such as interleukin-6, interleukin-12, interleukin-15, and tumor necrosis factor alpha, after coronavirus infection.\textsuperscript{24}

**Chronic Phase**

The usual lack of permeability of cerebral blood vessels represents a barrier to virus invasion, but also a barrier to viruses’ elimination in case of brain invasion. Given the lack of major histocompatibility complex antigen in nerve cells, the elimination of viruses is limited and depends on the role of cytotoxic T-cells and apoptosis of infected neurons.\textsuperscript{25}

The previously mentioned characteristics contribute to the chronic existence of viruses and may facilitate exacerbation of neurologic damage. Note that neuronal degeneration has been identified in SARS-CoV\textsubscript{2}-infected patients, and viral particles were identified in human brain tissue and CSF in multiple sclerosis patients.\textsuperscript{26}

**POTENTIAL NEUROLOGIC DISORDERS**

A previous study in Wuhan, when the pandemic was first described, demonstrated that 36% of 241 patients hospitalized for COVID-19 developed neurologic symptoms or secondary cerebral events. Others studies reported several categories of central and peripheral neurologic disorders in COVID-19 patients. Here we highlight the main neurologic disorders observed in COVID-19 patients to date:

**Nonspecific and Systemic Neurologic Symptoms**

Headache, myalgia, dizziness, and fatigue are the most common nonspecific symptoms seen in COVID-19 patients. These symptoms range from 30% to 45.5% and are more common as the disease is severe.

**Headache.** The most reported neurologic symptom in COVID-19 patients. Several studies showed headache as a symptom occurred in 8% to 34% of patients, and the intensity is often described as mild.\textsuperscript{16,27}

**Myalgia.** Myalgia has been commonly reported during the infection process. Some patients showed fatigue, muscle soreness, and elevated muscle enzyme levels, which may be related to the inflammation and muscle damage caused by the virus.\textsuperscript{28}

**Moderate Symptoms**

**Hyposmia, Hypogeusia, and Visual Dysfunction.** Hyposmia or anosmia and, less commonly, disturbed taste is common in patients with COVID-19, even in the absence of nasal symptoms, and may be initial and appear suddenly.\textsuperscript{29}

In a study reporting 417 patients with mild to moderate COVID-19 patients, 85.6% and 88% of the patients, respectively, described disturbances of smell and taste, and olfactory dysfunction was the initial symptom in 12% of the cases.\textsuperscript{30}

Other moderate nervous symptoms including deficit in visual function and neuralgia were also reported; however, an electrophysiology report of COVID-19 with peripheral nervous system symptoms is still lacking.\textsuperscript{2}

**Encephalopathy.** Infectious toxic encephalopathy, also known as acute toxic encephalitis, is a reversible brain dysfunction syndrome caused by factors such as systemic toxemia, metabolic disorders, and hypoxia during the process of acute infection.\textsuperscript{31} The basic pathologic changes include cerebral edema, with no evidence of inflammation on CSF analysis. Clinical symptoms are complex and diverse including headache, dysphoria, mental disorder, and delirium. Some rare severe forms may experience disorientation, loss of consciousness, coma, and paralysis.\textsuperscript{32}

**Epilepsy, Paralysis, and Consciousness Disorders.** Epilepsy, as well as paralysis and consciousness disorder, is a symptom associated with many underlying intracranial lesions and has been reported in COVID-19 patients. It may result from hypoxia, multiorgan failure, or metabolic and electrolyte derangements. This symptom may require specific medication and neurologic assessment. Hence it is plausible to expect clinical or subclinical acute symptomatic seizures and status epilepticus to happen in these patients.\textsuperscript{1,33}

**Severe Symptoms**

**Cerebrovascular Events.** Several categories of cerebrovascular events (intracerebral hemorrhage, ischemic stroke, and cerebral venous thrombosis) were recently reported in COVID-19 patients. **Intracerebral Hemorrhage.** Several cases have been reported in elderly COVID-19 patients with the usual risk factors, such as hypertension, diabetes, and underlying cardiac disease. Binding to ACE\textsubscript{2}, which is known to be a cerebrovascular protective factor, SARS-Cov-2 may cause abnormally elevated blood pressure. This hypertension, associated with the presence of thrombocytopenia and bleeding disorders, is a factor that may contribute and increase the risk of intracerebral hemorrhage in patients with COVID-19.\textsuperscript{34,35}

**Ischemic Stroke.** SARS-Cov-2 infection has been suggested to cause stroke. Current evidence suggests that COVID-19 patients...
commonly had neurologic symptoms manifested as acute stroke in 2.8% to 6%, and most (80%) were ischemic. A number of potential mechanisms by which COVID-19 might increase ischemic stroke risk have been reported. These include hypercoagulability as evidenced by raised D-dimer levels, exaggerated systemic inflammation (cytokine storm), and cardioembolism from virus-related cardiac injury.

**Acute Necrotizing Encephalopathy.** Acute necrotizing encephalopathy, a rare disorder leading to brain dysfunction, has been reported recently in COVID-19 patients. It results in seizures, liver problems, and mental disorientation. The disease is characterized by multifocal symmetric lesions in the brain, which affect the brainstem, thalami, cerebellum, and cerebral white matter. ANE is characterized by neuroinflammation resulting from a cytokine storm mediated mainly by the production of the interleukin-6. This systemic inflammation causes severe encephalopathy in the patient and may lead to stroke.

**Meningitis and Encephalitis.** The first case of COVID-19 with encephalitis was reported in Beijing, China. The man presented with convulsions and persistent hiccups. Neurologic examination revealed bilateral ankle clonus, bilateral positive Babinski sign, and meningeal irritation. The patient had a normal computed tomography scan. A lumbar puncture showed an increased opening pressure of 330 mm H2O and normal biochemical and laboratory neurologic assessment, with a negative medical history, with a negative nasopharyngeal swab. The SARS-CoV-2 ribonucleic acid was detected in CSF. Note that symptoms of meningitis or encephalitis may be the first symptoms, as well as the respiratory symptoms.

**Guillain-Barre Syndrome.** A case of Guillain-Barre syndrome (GBS) associated with SARS-CoV-2 infection has been described in a 62-year-old patient who presented motor weakness in the lower extremities and clinical symptoms of COVID-19 a week later. The CSF study showed a hyperproteinorachia (124 mg/dL) and absence of cells. Neuropsychologic examination revealed an increase in distal latencies and an absence of F-waves, pointing to a demyelinating form of GBS. The authors suggest that the patient was infected with SARS-CoV-2 at the onset of GBS symptoms, as she had lymphopenia and thrombocytopenia.

**Potential Long-Term Central Nervous System Consequences of COVID-19: Neurodegenerative and Demyelinating Disorders**

Given the chronic neuroinflammation and neuronal degeneration reported in SARS-CoV patients, as well as the viral particles found in multiple sclerosis patients, and considering that human neurodegenerative diseases often involve a gradual process that evolves, in some cases, over several decades, we think that current COVID-19 patients, especially with neurologic symptoms, may develop late and long-term neurologic complications. Hence they should be closely followed up, and future studies should consider late neurologic complications, such as demyelinating and degenerative disorders in these patients (e.g., polyneuropathies, Parkinson disease, multiple sclerosis).

**CURRENTLY**

Currently, there is convincing evidence that SARS-CoV-2, the etiologic agent of COVID-19, can affect the nervous system, with damage and neurologic alterations. Management of COVID-19 patients should include early clinical, radiologic, and laboratory neurologic assessment, with a close follow-up, especially in severe forms. Future studies should assess late and long-term consequences of current COVID-19 patients with neurologic involvement.

**REFERENCES**


25. Reinhold AK, Rittert HL. Barrier function in the peripheral and central nervous system—a review. Pflügers Arch. 2017;469:123-134.

Conflict of interest statement: The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received 13 May 2020; accepted 20 May 2020
Citation: World Neurosurg. (2020) 140:49-53.
https://doi.org/10.1016/j.wneu.2020.05.193
Journal homepage: www.journals.elsevier.com/world-neurosurgery
Available online: www.sciencedirect.com
18/7/8750/$ - see front matter © 2020 Elsevier Inc. All rights reserved.